Ionis announced FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS

If approved, tofersen will be the first treatment targeting a genetic cause of ALS and the next marketed Ionis-discovered antisense medicine FDA decision expected by April 25, 2023 CARLSBAD, Calif. , March 22, 2023 /PRNewswire/ — Ionis (Nasdaq: IONS) today announced the outcome of the U.S.